itrack-advange.png

THE ITRACK™ ADVANCE ADVANTAGE

For over a decade, Nova Eyes proprietary iTrack™ canaloplasty microcatheter has been used across the globe, combining pressurized viscodilation with catheterization over the entire 360º of the conventional outflow pathway, to effectively treat more than 100,000 glaucoma patients.* Building on that success and the clinically proven effectiveness of the iTrack™ technology, we are proud to introduce the next generation of iTrack™ – iTrack™ Advance.

The ground-breaking iTrack™ Advance takes the established effectiveness, accuracy and reliability of the original iTrack™ canaloplasty microcatheter, and combines it with an ergonomic, easy-to-use handheld injector.

CANALOPLASTY IN YOUR HANDS

Developed out of extensive research, innovation and feedback from surgeons, the iTrack™ Advance’s all-in-one handheld injector allows for streamlined insertion of the microcatheter into Schlemm’s canal. It also enables predictable, controlled and smooth advancement/retraction of the microcatheter through the canal. The clinically proven1,2 iTrack™ microcatheter is at the heart of the iTrack™ Advance. Measuring just 220 microns in diameter, it comprises a sophisticated set of inner workings including a proprietary fiber optic for illuminating the distal tip.

ADVANCING CANALOPLASTY TO THE NEXT LEVEL

For over a decade, Nova Eye’s proprietary iTrack™ canaloplasty microcatheter has been used across the globe, combining pressurized viscodilation with catheterization over the entire 360º of the conventional outflow pathway, to effectively treat more than 100,000 glaucoma patients.* Building on that success and the clinically proven effectiveness of the iTrack technology, we are proud to introduce the next generation of iTrack™ – iTrack™ Advance.

TRABECULAR MESHWORK

Up to 75% of outflow resistance is localized within the trabecular meshwork.1 The juxtacanalicular portion of the trabecular meshwork, which lies immediately adjacent to Schlemm’s canal, is thought to account for the majority of reduced outflow facility within the trabecular meshwork of POAG eyes. iTrack™ can effectively separate the compressed trabecular plates within the trabecular meshwork.

SCHLEMM’S CANAL

Up to 50% of decreased outflow facility may be caused by blockages within the canal.

The dimensions of the lumen of Schlemm’s canal are smaller in POAG eyes1 and can account for up to 50% of decreased outflow facility in POAG eyes.2 iTrack™ can effectively break adhesions within Schlemm’s canal, in addition to dilating the canal up to twice its size.

COLLECTOR CHANNELS

Up to 90% of collector channels may be blocked in glaucomatous eyes

Up to 90% of collector channels may be blocked by herniations of the trabecular meshwork in POAG eyes.1,2 These herniations into the collector channels result in increased outflow resistance.1,2 iTrack™ can effectively push out herniations out of the collector channels and dilate the collector channels to reduce outflow resistance.